Filing
📈 Stocks
MetaVia Completes Phase 1 Study Visit for DA-1726 Liver Disease Candidate
(just now)
MetaVia advances its DA-1726 liver disease program after completing Phase 1 Part 3A, with full data expected in Q1 2027 and a…